Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

676 recalls · Class II, newest first

Class II · Moderate risk

clomiPRAMINE Hydrochloride

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 16714-850-01 D-0153-2026
Class II · Moderate risk

clomiPRAMINE Hydrochloride

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 16714-849-01 D-0152-2026
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 60687-572-32 D-0103-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 68084-997-01 D-0102-2026
Class II · Moderate risk

Prazosin Hydrochloride

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit

Ongoing Nitrosamine impurity Amerisource Health Services LLC NDC 68084-996-01 D-0101-2026

Recalls by year